Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Interest Expense

Cost of servicing the company's debt during the period.

Johnson & JohnsonNYSE: JNJ

Interest Expense · Q3 FY2026 · quarter ended Sep 2026

Interest expense declines year over year

Q3 FY2026 interest expense of $31M fell 87.3% year over year, behind the -10.7% change in trailing-twelve-month interest expense. Sequentially, it fell 89.0% from the prior quarter. Over 3 fiscal years it compounded at +52.1% a year.

Context

  • Interest expense amounted to 1.0% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -87.3% toward the trailing-twelve-month pace of -10.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$31M-89.0% QoQ
Last fiscal yearDec 2025
$971M+28.6% YoY
LTMSep 2026
$798M-10.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-87.3%——
1 year+28.6%——
3-year CAGR+52.1%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
971M USD
Year-over-year change
+28.6%
4-year CAGR
+51.8%

Interest Expense vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.7% is the 9th highest of 11, against a peer median of -0.7%.
  • Interest expense amounts to 0.8% of revenue for JNJ, versus a peer median of 3.1%.
JNJ Competitors
Interest Expense for JNJ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABBVAbbVie Inc.LTM Sep 2026$2.88B USD-0.1%+9.1%4.4%
PFEPfizer Inc.LTM Jun 2026$2.7B USD-4.7%+29.2%4.2%
AMGNAmgen Inc.LTM Jun 2026$2.67B USD-9.7%+25.1%7.0%
AZNAstraZeneca PLCLTM Sep 2026$1.77B USD+7.2%+8.4%2.8%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$1.73B USD-12.6%+15.4%3.5%
NVSNovartis AGLTM Jun 2026$1.39B USD+26.0%+12.5%2.5%
MRKMerck & Co., Inc.LTM Jun 2026$1.26B USD-1.0%+12.2%1.9%
GILDGilead Sciences, Inc.LTM Jun 2026$998M USD-0.3%+3.1%3.3%
JNJJohnson & JohnsonLTM Sep 2026$798M USD-10.7%+52.1%0.8%
GSKGSK plcLTM Jun 2026£690M GBP+6.8%-7.1%2.1%
SNYSanofiLTM Jun 2026€591.41M EUR-39.7%+17.6%1.2%
Peer median (excluding JNJ) —-0.7%+12.3%3.1%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.